Header Logo

Connection

ALEXANDER LAZAR to Neoplasms

Back to Details
This is a "connection" page, showing publications ALEXANDER LAZAR has written about Neoplasms.
ALEXANDER LAZAR
Connection Strength
1.456
Neoplasms
  1. Human and machine: Better at pathology together? Cancer Cell. 2022 08 08; 40(8):806-808.
    View in: PubMed
    Score: 0.130
  2. PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. J Pathol. 2018 04; 244(5):512-524.
    View in: PubMed
    Score: 0.096
  3. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
    View in: PubMed
    Score: 0.085
  4. New, tolerable ?-secretase inhibitor takes desmoid down a notch. Clin Cancer Res. 2015 Jan 01; 21(1):7-9.
    View in: PubMed
    Score: 0.076
  5. Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers. Science. 2024 09 06; 385(6713):eadk9217.
    View in: PubMed
    Score: 0.038
  6. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. Nat Commun. 2024 Aug 25; 15(1):7312.
    View in: PubMed
    Score: 0.038
  7. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res. 2024 May 15; 30(10):2121-2139.
    View in: PubMed
    Score: 0.037
  8. Pan-cancer proteogenomics characterization of tumor immunity. Cell. 2024 Feb 29; 187(5):1255-1277.e27.
    View in: PubMed
    Score: 0.036
  9. Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 2023 08 31; 186(18):3921-3944.e25.
    View in: PubMed
    Score: 0.035
  10. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023 08 31; 186(18):3945-3967.e26.
    View in: PubMed
    Score: 0.035
  11. Deep learning integrates histopathology and proteogenomics at a pan-cancer level. Cell Rep Med. 2023 09 19; 4(9):101173.
    View in: PubMed
    Score: 0.035
  12. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature. 2023 Aug; 620(7974):651-659.
    View in: PubMed
    Score: 0.035
  13. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562.
    View in: PubMed
    Score: 0.034
  14. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.032
  15. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.031
  16. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021 12; 32(12):1626-1636.
    View in: PubMed
    Score: 0.031
  17. A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. J Pathol. 2021 06; 254(2):109-120.
    View in: PubMed
    Score: 0.030
  18. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
    View in: PubMed
    Score: 0.029
  19. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.029
  20. The International Collaboration for Cancer Classification and Research. Int J Cancer. 2021 02 01; 148(3):560-571.
    View in: PubMed
    Score: 0.029
  21. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 2020 05 11; 37(5):639-654.e6.
    View in: PubMed
    Score: 0.028
  22. T-cell trafficking plays an essential role in tumor immunity. Lab Invest. 2019 01; 99(1):85-92.
    View in: PubMed
    Score: 0.025
  23. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. JAMA Oncol. 2018 06 01; 4(6):838-841.
    View in: PubMed
    Score: 0.024
  24. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018 04 05; 173(2):291-304.e6.
    View in: PubMed
    Score: 0.024
  25. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018 04 05; 173(2):305-320.e10.
    View in: PubMed
    Score: 0.024
  26. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10.
    View in: PubMed
    Score: 0.024
  27. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018 04 05; 173(2):338-354.e15.
    View in: PubMed
    Score: 0.024
  28. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018 04 05; 173(2):355-370.e14.
    View in: PubMed
    Score: 0.024
  29. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 04 05; 173(2):371-385.e18.
    View in: PubMed
    Score: 0.024
  30. The Immune Landscape of Cancer. Immunity. 2018 04 17; 48(4):812-830.e14.
    View in: PubMed
    Score: 0.024
  31. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep. 2018 04 03; 23(1):181-193.e7.
    View in: PubMed
    Score: 0.024
  32. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018 04 03; 23(1):227-238.e3.
    View in: PubMed
    Score: 0.024
  33. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253.
    View in: PubMed
    Score: 0.024
  34. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641.
    View in: PubMed
    Score: 0.024
  35. A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. Arch Pathol Lab Med. 2017 Dec; 141(12):1679-1685.
    View in: PubMed
    Score: 0.023
  36. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.022
  37. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.021
  38. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep. 2016 Jan 20; 6:19649.
    View in: PubMed
    Score: 0.021
  39. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4.
    View in: PubMed
    Score: 0.021
  40. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.019
  41. The Cancer Genomics Resource List 2014. Arch Pathol Lab Med. 2015 Aug; 139(8):989-1008.
    View in: PubMed
    Score: 0.019
  42. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 03; 109(5):1085-92.
    View in: PubMed
    Score: 0.017
  43. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009 Sep; 16(9):2502-9.
    View in: PubMed
    Score: 0.013
  44. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005 Jan; 132(2):415-27.
    View in: PubMed
    Score: 0.010
  45. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother. 1999 Jun; 8(3):255-62.
    View in: PubMed
    Score: 0.007
  46. Changes in serum proteins during methylcellulose-induced regression of Murphy-Sturm lymphosarcoma. Lab Invest. 1963 Jan; 12:25-32.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.